Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions

DRUG: Dolutegravir 50 mg tablet
DRUG: Dolutegravir 50 mg oral granules

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]